Q-REstrain is a supportive approach based on microRNA molecules with the ability to regulate the expression of specific target genes, a process that under physiological conditions happens naturally. The underlying mechanism, RNA interference (RNAi), has been successfully applied in addressing various diseases, including cancer, viral, and respiratory conditions. By targeting and degrading messenger RNA (mRNA) molecules, RNAi helps suppress the production of proteins associated with disease progression, thus supporting endogenous regulatory processes.

Q-REstrain utilizes microRNAs isolated from the patient’s own sample, designed to degrade specific, overexpressed mRNA molecules. This process helps restore normal gene expression levels.

As a non-manipulated, autologous approach, Q-REstrain is selected and isolated uniquely for each patient and is available exclusively through the RGCC network.

Clavic-Q-RE is a non-manipulated, adoptive cell preparation aiming to support immune function. Clavic-Q-RE contains different cell populations isolated from the patient’s sample. They include monocytes, natural killer cells, as well as dendritic cells that are already activated in vivo against tumor antigens, which are expressed on cancer samples, cytotoxic T lymphocytes, and plasma cells that have already been differentiated in vivo against tumor antigens.

Clavic-Q-RE is for autologous use only and is provided through the RGCC network.

Autologous Tumor Antigens Prep (ATA) introduces a new approach to supporting the immune system and maintaining balanced immune function. The body's own cells are specifically designed to recognize and destroy cancer cells. We use the cellular fragments of dying tumor cells (CTCs). These include organelles, mitochondria, cell membranes, cellular RNA and DNA, and tumor protein fragments.

The aim of dendritic cell preparation is to help sustain a balanced immune function. Under physiological conditions, specific immune cells are used to target cancer cells. This method uses dendritic cells, which can already natively recognize specific antigens on the surface of cancer cells. Thanks to improved tumor defense and a reduction in systemic side effects, this innovation is considered a promising supportive approach.